Pulmonx Corp
Pulmonx Corp is a U.S.-based medical device company focused on minimally invasive treatments for severe emphysema and other advanced chronic obstructive pulmonary disease (COPD) patients. Its portfolio centers on the Zephyr Endobronchial Valve, supported by the Chartis assessment system, LungTraX patient identification software, and the AeriSeal System under development and clinical evaluation.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueEndobronchial valves and delivery tools used to treat severe emphysema.
Diagnostic and procedural tools used to assess collateral ventilation and guide treatment.
LungTraX software used to identify patients who may be eligible for Zephyr treatment.
Synthetic polymer foam system under clinical development for lung lobe occlusion.
Customers
Pulmonx sells primarily to hospitals, interventional pulmonologists, and distributors that support bronchoscopic lung volume reduction procedures. Demand depends on physician adoption, hospital program development, reimbursement access, and the number of patients identified as eligible for treatment. The company also works with patient advocacy and education channels to expand awareness among COPD patients and referring clinicians.
Buy valves, catheters, and Chartis tools to establish and expand emphysema treatment programs.
Use the system in procedures and drive clinical adoption through patient selection and treatment.
Purchase and resell products in select markets where direct sales are not used.
Influence demand through diagnosis, referral, and awareness of minimally invasive treatment options.
Strategy
Pulmonx is focused on expanding Zephyr Valve adoption by building hospital programs, training physicians, and increasing patient awareness in severe emphysema. It also seeks to broaden its addressable market through clinical evidence, regulatory work, and next-generation products such as AeriSeal, while extending commercial reach in international markets where reimbursement is established or improving.
The core growth lever is broader physician and hospital adoption of Zephyr Valve therapy.
Coverage and published outcomes are critical for hospital uptake and payer acceptance.
International markets provide additional procedure volume but require local execution and reimbursement readiness.
Pipeline expansion can increase the addressable market and reduce reliance on one product family.
Geography
Q1/2026Pulmonx is headquartered in the United States and sells through a direct commercial organization there, while international markets use a mix of direct and distributor-based sales. Management discloses meaningful revenue from both the United States and international markets, with international sales spanning Europe, Asia Pacific, and other select countries. Geography matters because reimbursement, physician training, and regulatory approval differ by market and affect adoption speed.
Share of the revenue the company reports by geography.
Risks
Pulmonx is exposed to adoption risk because its business depends heavily on one core therapy, physician training, and hospital program development. It also faces reimbursement, regulatory, clinical evidence, and international execution risks, all of which can slow procedure growth or limit market access. As a medical device company, it must also manage product liability, cybersecurity, and foreign exchange exposure across markets.
- Product concentrationImpact: HighLikelihood: Medium
Substantially all revenue comes from a limited set of products, especially Zephyr Valve.
Exposure - Reimbursement dependenceImpact: HighLikelihood: Medium
Procedures require coding, coverage, and payment support to be broadly adopted.
Exposure: Changes in payer policy can reduce hospital willingness to offer the procedure.
- Clinical and product liabilityImpact: HighLikelihood: Medium
The therapy is used in invasive procedures on high-risk COPD patients.
Exposure: Adverse events or weak clinical evidence could slow adoption.
- Limited commercial experienceImpact: MediumLikelihood: High
The company states it has limited experience marketing and selling its solution.
Exposure: Sales execution and physician education are central to growth.
- International executionImpact: MediumLikelihood: Low
Markets outside the U.S. require local reimbursement, regulatory, and channel management.
Exposure: Distributor performance and local market access can vary significantly.
Accounting
Judgemental itemsSales include devices, consoles, usage fees, and distributor transactions with different timing patterns.
Impact: Can shift revenue between periods depending on shipment and usage timing.
The procedure is elective and management notes first and third quarter seasonality.
Impact: Quarterly revenue and margins may not be directly comparable.
Operating lease obligations are material and affect future cash commitments.
Impact: Impacts liabilities, expense recognition, and liquidity analysis.
Outstanding term loans and credit agreements require ongoing accounting and disclosure.
Impact: Affects leverage, interest expense, and covenant monitoring.
AeriSeal and other pipeline programs depend on trial outcomes and regulatory approvals.
Impact: Can affect capitalization, expense timing, and future asset values.
Similar listed companies
Publicly listed companies with a comparable business focus.
Pulmatrix, Inc.
PULM · Pharmaceutical Preparations
Electromed, Inc.
ELMD · Electromedical & Electrotherapeutic Apparatus
Savara Inc
SVRA · Pharmaceutical Preparations
MiMedx Group, Inc
MDXG · Surgical & Medical Instruments & Apparatus
MIMEDX Group develops and commercializes regenerative biologic products used by clinicians to treat chronic wounds, burns, and surgical applications.
Vertex Pharmaceuticals Incorporated
VRTX · Pharmaceutical Preparations
Vertex Pharmaceuticals is a U.S.-based biotechnology company focused on discovering, developing, and commercializing medicines for serious diseases.
Corvex, Inc.
MOVE · Services-Computer Processing & Data Preparation
Last updated: 24/09/2026